The mineralocorticoid system, cardiometabolic health and its interplay with adipose tissue
Journal of Endocrinology · 2024
DOI: 10.1530/joe-24-0119 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Endocrinology, 2024. Verfasst von Moe Thuzar und 2 weiteren Autor:innen. Beteiligte Einrichtung: Endocrine Hypertension Research Centre, University of Queensland Frazer Institute and Princess Alexandra Hospital, Brisbane, Queensland, Australia. Hauptthemen laut MEDLINE: Adipose Tissue, Mineralocorticoids, Cardiovascular Diseases, Renin-Angiotensin System. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 140 Literaturangaben.
Abstract (Originalsprache)
The mineralocorticoid system, comprising the renin-angiotensin-aldosterone system (RAAS) and associated receptors, is traditionally viewed as a regulator of sodium and fluid balance and blood pressure (BP), with the main mineralocorticoid hormone aldosterone acting via the mineralocorticoid receptor (MR) in distal renal tubules. Over the past few decades, there has been a wider understanding of the role of the mineralocorticoid system in regulating both classical BP-dependent and non-BP-dependent systemic effects. Mounting evidence indicates the novel role of the mineralocorticoid system in cardiometabolic health, with excess mineralocorticoid system activity being associated with adiposity, diabetes, insulin resistance and cardiovascular diseases independent of its effect on BP, and RAAS blockade and MR antagonists offering protection against cardiometabolic dysfunction. The metabolic manifestations of mineralocorticoid system overactivation are mainly mediated by their interactions with adipose tissue, which orchestrates energy, lipids, and glucose homeostasis via effects on the functions of brown and white adipocytes and immune cells. Adipose tissue can, in turn, influence mineralocorticoid system activity by harboring its own RAAS system and by releasing mineralocorticoid-secretory factors/adipokines, resulting in further progression of cardiometabolic dysfunction. This article discusses the interplay between the mineralocorticoid system and adipose tissue in the pathophysiology of cardiometabolic diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Endocrine Hypertension Research Centre, University of Queensland Frazer Institute and Princess Alexandra Hospital, Brisbane, Queensland, Australia.
- Department of Endocrinology & Diabetes, Princess Alexandra Hospital, Brisbane, Queensland, Australia.
ORCID-Profile: Moe Thuzar
Zitieren
APA
Thuzar, M., Abdul Halim, M., & Stowasser, M. (2024). The mineralocorticoid system, cardiometabolic health and its interplay with adipose tissue. Journal of Endocrinology. https://doi.org/10.1530/joe-24-0119
Vancouver
Thuzar M, Abdul Halim M, Stowasser M. The mineralocorticoid system, cardiometabolic health and its interplay with adipose tissue. Journal of Endocrinology. 2024. doi:10.1530/joe-24-0119
BibTeX
@article{Thuzar2024,
author = {Thuzar, Moe and Abdul Halim, Muthanna and Stowasser, Michael},
title = {The mineralocorticoid system, cardiometabolic health and its interplay with adipose tissue},
journal = {Journal of Endocrinology},
year = {2024},
doi = {10.1530/joe-24-0119}
}
EUVIMED